Senesco Technologies Reports Results of Preclinical Animal Sepsis Study

Senesco Technologies reported that mice treated with Senesco's proprietary technology have shown a marked survival benefit in the lethal sepsis study conducted at the University of Virginia by W. Michael Scheld.

Sepsis is a condition in which the immune system's rapid inflammatory response to a severe infection can cause organ damage and result in death and is the leading cause of death in noncoronary intensive care units in the U.S.

The study was conducted using a mouse model for sepsis and was designed to test Senesco's Factor 5A inhibition technology's ability to protect septic mice from death using different dosing schedules. In this model, for groups that received Senesco's Factor 5A inhibitor, survival ranged from 20 percent to 100 percent of the mice, depending upon mouse strain and dosing regime. None of the untreated mice survived.